Pafolacianine, an imaging drug that can help surgeons identify ovarian cancer lesions, has recently been accorded FDA approval. Pafolacianine is administered intravenously before surgery and binds to folate receptors (a type of biomarker), which often are overexpressed in ovarian cancer. Under fluorescent light, pafolacianine illuminates cancerous tissue, which is not always detected intraoperatively.
Ovarian Cancer is the 5th leading cause of cancer deaths in women in the United States.
In a recent study, researchers evaluated pafolacianine in ovarian cancer patients scheduled to undergo surgery. Among 134 women in the trial who received pafolacianine, 27% had cancerous lesions that conventional detection methods would have missed. Perhaps, the routine use of pafolacianine will ultimately provide significant beneficial outcomes for ovarian cancer patients undergoing surgery for the treatment of their disease.
Learn more about:
About Women’s Cancer Research Foundation
The Women’s Cancer Research Foundation (WCRF) is one of the most active research organizations in the nation. We are dedicated to studying and evaluating novel treatments for women afflicted with breast, ovarian, endometrial, and cervical cancers. The WCRF persistently endeavors to make a difference in women’s lives by offering them hope, strength, and progress.
Laguna Beach, CA 92651
PH: (949) 642-5165
Follow Us On Social Media:
Comments